Published: Feb 03, 2021 By Heather McKenzie
Cross-continental drug development and commercialization deals are good for business, and imperative for patients to receive access to the most valuable scientific breakthroughs. This month has already brought a number of these partnerships for the treatment of cancer and other diseases with a significant medical need. Here’s a look at four of them.
Illumina and Sequoia Capital China Incubating Genomics Talent
On Monday, leading DNA sequencing and array-based technologies company,
, announceda deal with global venture capital firm, Sequoia Capital China, to incubate life sciences startups specializing in genomics.
Accepted companies will benefit from $500, 000 investment and business guidance and a minimum of $100, 000 prioritizing investments from Sequoia Capital China in the next series of financing, along with access to Illumina’s sequencing systems, reagents, and genomics knowledge.
Published: Feb 02, 2021
Cross-continental drug development and commercialization deals are good for business, and imperative for patients to receive access to the most valuable scientific breakthroughs. This month has already brought a number of these partnerships for the treatment of cancer and other diseases. Here’s a look at three of them.
Illumina and Sequoia Capital China Incubating Genomics Talent
Yesterday, leading DNA sequencing and array-based technologies company, Illumina, announced a deal with global venture capital firm, Sequoia Capital China, to incubate life sciences startups specializing in genomics.
Accepted companies will benefit from $500, 000 investment and business guidance and a minimum of $100, 000 prioritizing investments from Sequoia Capital China in the next series of financing, along with access to Illumina’s sequencing systems, reagents, and genomics knowledge.